

Audit 2024

Contact:

Tumorzentrum Hirslanden Zürich

Witellikerstrasse 40

8032 Zürich

T +41 44 387 96 62

tumorzentrum.hirslanden@hirslanden.ch

open studies

breast cancer

name of study

Ascent-03 study

target group/ short description

A randomized, open-label, phase 3 study of sacituzumab govitecan versus treatment of physician's choice in patients with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express PD-L1 or in patients previously treated with anti-PD-(L)1 agents in the early setting whose tumors do express PD-L1

Ascent-04 study

A randomized, open-label, phase 3 study of sacituzumab govitecan and pembrolizumab versus treatment of physician's choice and pembrolizumab in patients with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express PD-L1

EKIB study

Analysis of human breast tumor heterogeneity and immune cell infiltrates and their relevance for patient outcome by mass cytometry.

EXPERT- study (ANZ 1601/ BIG 16-02)

Clinical trial which presents a unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence (molecular luminal A-breast cancer)

HER2CLIMB-05 (Seagen) study

A study of tucatinib or placebo with trastuzumab and pertuzumab for metastatic HER2+ breast cancer.

LidERA-study (Roche G042784)

A study evaluating the efficacy and safety of adjuvant Giredestrant compared with physician's choice of adjuvant endocrine monotherapy in participants with estrogen receptor-positive, HER2-negative early breast cancer (LidERA Breast Cancer).

Mallorca-study

Surgical **MA**rker **Lo**ca**LI**sation **OR** **C**lip and wire **A**pplication for targeted axillary dissection in node positive breast cancer patients.

POLAR-study (IBCSG 59/19)

Palbociclib for HR Positive / HER2-negative isolated locoregional recurrence of breast cancer (POLAR).

PROMs

Patient reported outcomes after oncoplastic breast conserving surgery.

SASCIA-study (Gilead)

Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.

SERENA 4-study (Astra Zeneca)

A comparative study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in patients with ER-Positive HER2 negative breast cancer who have not received any systemic treatment for advanced disease (SERENA-4).

	TAXIS-study (SAKK 23/16)	Tailored AXillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS).
	VISION-study (SAKK 23/18)	Vacuum assisted biopsy Immediately before surgery as an Intra- or pre-Operative surrogate for patient response to neoadjuvant chemotherapy for breast cancer (VISION I)
urogenital tumors	PCO study (Prostate Cancer Outcome)	Patient reported outcome measurement of patients with prostate cancer with global uniform patient questionnaire.
	Ironman study	The IRONMAN registry collects information about a man's type of prostate cancer, their treatment and what side effects they may be experiencing.
	MRI bladder cancer study	Multiparametric Magnetic Resonance Imaging (MRI) to improve bladder cancer staging and treatment decision-making.
	SAKK 06/ 19 study	Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with MIBC.
gastrointestinal tumors	EDIUM study	Patient-reported outcome study for colon cancer patients: Ergebnisqualität bei Darmkrebs: Identifikation von Unterschieden und Massnahmen zur flächendeckenden Qualitätsentwicklung (Quality of Experience in the case of colon cancer: identification of differences und actions to be taken for a comprehensive quality development)
	ESODATA study	International standardized online database für outcomes of the patients receiving evaluation and/ or treatment für esophageal diseases of benign and malignant conditions.
	IBDS -CRC study	Image-based ex vivo drug screening and genomics/transcriptomics for patients with colorectal cancer stage II, III or IV
	Patient-derived organoid generation study	Patient-derived organoid generation in pancreatic cancer: a single centre, open-label, single arm feasibility study.
	PREFER-study	Endoscopic management of patients with T1bN0M0 esophageal adenocarcinoma.
	Quality assurance study for duodenal tumors	Quality assurance study of perioperative morbidity and post-surgical follow up of hepato-duodeno-pancreatic surgery.
	Quality assurance study for pancreatic tumors	Quality assurance study of perioperative morbidity and post-surgical follow up of pancreatic surgery.
	ROBOT-2 study	Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial.
	Tiger study	Distribution of lymph node metastases in esophageal carcinoma.
	hematological systemic diseases	Abbvie Valor-Studie
EBMT-Register		Registry for patients that received a haematopoietic stem cell transplantation or CAR T-cell therapy.
SAKK EMCL-Registry		The registry of the European Mantle Cell Lymphoma study group - MCL: Disease pattern, treatment algorithms and mechanisms of relapse.

neuro-oncological tumors

Gliostar study

A study to evaluate safety and efficacy of L19TNF plus lomustine in patients with glioblastoma at first progression (GLIOSTAR).

Meningiom-study

A population-based study on incidence, survival and molecular characteristics of meningioma in the Canton of Zurich, Switzerland.

PERGOLA-study

Pembrolizumab for newly diagnosed glioblastoma: a prospective, open-label, single-arm, multicenter phase II study.

multi-organ studies

AGE-1 Studie

Evaluation of forensic methods for age estimation of patient with cancer and a control group.

Roche GLYCART Studie

Ex vivo modeling of fresh tumor tissue.

